Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you. We need it.
Thanks. Appreciate your posts.
GLTA
Yes, there are some truth in "Maybe". lol
Pogue, you are absolutely right about it.
When I learn that stock price goes down without apparent reasons I believe that it goes up without any apparent reasons.
Only hope is we are at THE bottom.
GLTA
Really but it’s still going down at this moment, sigh.
.
Interesting that the title suggests the new guidance is for only "Cancer" Drugs and Biologics. How come.
Never seen a stock move like this today.
200% up mid-day ended up 5.7% Eod.
What a daydream.
Some people lost 66% but most are traders and probably not holding it weekend.
What drove pps today? I don't find any news;a rumor?
GLTA
Awesome! It looks like Dr. M is going to be reeeeeee~ally ready.
I thought his question was 'why not yesterday at the recent peak?
It appears to be an arranged trade, doesn’t it.
That's great hope. They are broadening their show-window.
Who knows that's for Christmas shopping this year! Ha
Daniel Klamer, Anavex Vice Presidant is the Chairperson at The New York Academy Of Sciences symposium in Boston,MA today.
No PR about it. I guess that is not news material.
It ends at 6:05 p.m. EST. probably by now.
He will speak tomorrow too.
------------------------------------------------------------------
TARGETING AND DEVELOPING NOVEL CNS TARGETS
Back Bay B
1:50 Chairperson’s Opening Remarks
Daniel Klamer, PhD, MBA, Vice President, Business Development & Scientific Strategy, Anavex Life Sciences Corp.
1:55 ANAVEX 2-73, a Sigma-1 Receptor Agonist, in Phase IIb/III for the Treatment of Alzheimer’s Disease
Daniel Klamer, PhD, MBA, Vice President, Business Development & Scientific Strategy, Anavex Life Sciences Corp.
Anavex Life Sciences Corp.’s lead drug candidate, ANAVEX 2-73, recently completed a successful Phase IIa clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by activating the sigma-1 receptor. Full genomic analysis of the study participants resulted in the identification of genetic mutations linked to treatment response. Clinical studies in several indications are planned or underway utilizing a precision medicine approach.
---------------------------------------------------------
Sept. 27 : NON-OPIOD PAIN DRUG DEVELOPMENT SUMMIT - Boston, MA
2:30 Case Study: ANAVEX®1066, a Sigma-1 Receptor Antagonist, as a Therapeutic Candidate for Pain
- Daniel Klamer : VP, Business Development & Scientific Strategy, Anavex Life Sciences Corp.
• Strong scientific rational for the use of Sigma-1 Receptor antagonists in pain
• ANAVEX®1066 have demonstrated efficacy in several different pain models
• ANAVEX®1066 is safe in doses exceeding the observed efficacious ranges
http://www.non-opioiddrugdevelopment.com/
That is fair.
We did get 40% gain on 9 mil volume if I remember correct.
Maybe you meant SP went back down where it was in about month?
Thank you for your earlier message. I knew it.
GLTY
It's hard to tell if you are serious or not.
Two trial had started already and pps have dropped.
I don't know what the start of Rett trial will bring- probably nothing much.
I am rather betting on "recognition of A2-73" by the industry/investors.
Yes like $100Mil x16 to 1.6 Bil by "recognition" for a drug in phase 2 that Fireman was talking about?
GLTA
Call 411
Over $3.0 and over 10%
Sounds like a good plan.
Btw did lbsr go to the moon? haha
This is the same media company that aired the painter, piano player, golfer with Dr. Macfarlane on TV in 2015, ABC NEWS in Australia?
And maybe article below will be aired in 4 hours?
For more on this story, watch 7.30 tonight.
Hope it is an early sign of Dr.M's actions to come.
==================================================
Climate scientist Barrie Pittock has spent his career asking questions and testing theories and now the Nobel Peace Prize winner's mind is part of another study, one that challenges a long-held view of what causes Alzheimer's disease.
Five years ago, the acclaimed academic noticed he was becoming forgetful and was struggling with simple tasks like reading maps. Brain scans confirmed he was in the early stages of the degenerative condition.
Now, Dr Pittock is participating in a trial with Australian researchers and sees it as one of his final contributions to science.
"I want to be useful. I wanted to do something that had some practical value to humanity," he said.
Australian doctors say it is time for a radical new approach to Alzheimer's disease after more than 100 drug trials and studies have failed to find a treatment that stops the devastating brain condition.
The leading hypothesis of Alzheimer's disease is that it's caused by an accumulation of a sticky plaque known as beta amyloid, which strangles healthy brain cells and destroys memory function.
Over the past 30 years, with all the drugs that have been developed globally to flush out this plaque, the failure rate has been nearly 100 per cent.
Now a small, but growing group of scientists is examining everything from gut health to hormone imbalance and insulin resistance as the new possible frontiers of understanding Alzheimer's.
"There's no point flogging the same dead horse," associate professor Stephen Macfarlane, head of clinical services at HammondCare, said.
"If you try too many failed attempts, the drug companies back out of drug development and don't pursue it.
"The number of people living with dementia will double in the next 20 years if we don't do anything."
He's leading the second phase of a trial for the experimental drug Anavex 2-73, which helps to remove amyloid plaque, but also preserves nerve cells and reduces inflammation in the brain.
"One of the hopes that we have for this trial is it's showing a completely different approach using a different scientific method," Dr Macfarlane said.
Some of the people who took part in the first phase of the trial experienced remarkable recoveries.
"We've had people who previously had been accomplished painters, artists, piano players, who resumed those activities," Dr Macfarlane said.
"Those sorts of improvements are much more meaningful, in my view, than a two-point improvement on a memory test because they illustrate really life-changing benefits to a person."
Dr Pittock was among 2,000 climate scientists who shared the 2007 Nobel Peace Prize with former US vice-president Al Gore.
He said he had some hope, "maybe a 20 per cent chance".
"At 80, time's up for a lot of people. You've got to be philosophical about the diagnosis," Dr Pittock said.
Diana, his wife of 53 years, hopes the experimental drug will buy her more time with her husband.
"We met during Easter of 1965 and we were married that September. We just decided we were right for each other," she said.
If not plaque, then what?
Scientists who believe plaque could be a symptom rather than the cause of Alzheimer's disease are now putting all their efforts into preventing it developing in the brain in the first place.
"We are now at a stage where we can diagnose Alzheimer's well before the symptoms appear — at least 20 years earlier," Professor Ralph Martins, an Alzheimer's researcher from Macquarie University, said.
"And this is the time when we think we can have the greatest impact because the brain is relatively preserved."
Professor Martins is conducting a trial to discover whether receiving shots of testosterone and taking fish oil could stave off the plaque.
"What hormones do is basically suppress the production of this amyloid," he said.
"In men, it's testosterone, and in women it's estrogen. Once we get older, our testosterone falls, that's when the amyloid starts rising."
When Max McGown heard about the study, he volunteered immediately.
The 67-year-old Sydney retiree watched Alzheimer's disease slowly rob his mother Gladys of her memories and her independence, and he became convinced he was next.
"I sometimes stumble for a word that I think I should know and scratch my head and wonder why I can't remember it until 3:00am the next morning," Mr McGown said.
"So, I guess it's just this feeling that I hope this is not one of the symptoms."
But after undergoing a PET scan, and waiting three agonising days for the results, Mr McGown was surprised to receive good news.
"Turns out I don't have the amyloid in the brain. I don't have the tendency to develop the disease, so I'm very pleased about that," he said.
"It's good news for me, but I hope something comes out of the trial that helps other men."
For more information on the Anavex 2-73 trial, visit their website. To volunteer for the Australian Alzheimer's Research Foundation's testosterone trial, visit their website.
Whoa......attendees: many BP's !!!
AbbVie
Albany Medical CollegeAlzheimer’s Association
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Amgen
Anavex Life Sciences Corp.
Brigham and Women’s Hospital, Harvard Medical School
C Wilmot Consulting, LLC
C&EN, Chemical & Engineering News
Century Innovations
Charles River Laboratories International, Inc.
Columbia University
Columbia University Irving Medical Center
Columbia University Medical Center
Emory University School of Medicine
Enterin Inc.
Genervon Pharmaceuticals
Georgetown University
Graduate School, City University of New York
H. Lundbeck A/S
Harvard Medical School
Hunter College, CUNY
Indiana University School of Medicine
INmune Bio
Intra-Cellular Therapies, Inc
Janssen Research & Development, LLC
Johnson & Johnson
Jones Trading Institutional Services
Kallyope Inc.
Magnolia Neurosciences
Memorial Sloan-Kettering Cancer Center
MerciaPharma
Merck Research Laboratories
Monash University
National Geographic
Nature Research
Novartis Institutes for Biomedical Research
NYU School of Medicine
OSI Pharmaceuticals, LLC
Otsuka America Pharmaceutical, Inc.
Pfizer
Pfizer Inc
Pfizer Inc.
Pfizer Ventures
Pleasantville Friends of STEM,Inc.
Psychology Today
Regeneron Pharmaceuticals, Inc
SQI Diagnostics
St. Johns University, NY
SUNY Upstate Medical University
Tabasco Health Care
The Columbia University School of Medicine
The Icahn School of Medicine at Mount Sinai
The Jackson Laboratory
The Lessac Group
The New York Academy of Sciences
The Rockefeller University
Trillium Medical Ventures LLC
University of Kentucky
University of Washington
Weill Cornell Medicine
You did it again. Thanks! The symposium looks like for Anavex.
I hope what had happened at AAIC last July does not happen again -
AVXL's press release was berried/hidden cunningly on their website.
Garbage talk.
How precise your prediction was!
Amazing ...... close at 2.49
No retail but no one reported their buy after 9 mil day in early July.
How can that happen?
Maybe Currah for the 2nd scene(scam).
What can be A GAME CHANGER if AVXL is Not?
Thank you for 9% gain and doubled volume today.
I guess people DO read message board and put money on stocks.
Astonishing title! Thank you.
Why 5% drop on good news? It’s not?
.
Thank. We were hovering around even $4 after the drop from $14.
After almost 3 years............... losing patience and faith.
I’m really worried now, down 40% here. Wife asks me sell and run to the mountain. I’m sure many feel this way.
Everybody appreciated your sharing of the conversation with Dr. M last spring.
Do you see if he has failed or changed for anything that he would do since the shareholder meeting?
I’m not sarcastic or anything but one of frustrated shareholders.
Thanks
Tom, Did AVXL lose the 2.50 floor today?
Thank you for doing that !
Till then all sells like this morning, sigh......
I've been glad myself for Anavex to have capacities to work with other governments also.
Are you talking about the trial that CEO said it would start before end of last year?
Just unbelievable are that and current pps.
Wow, you wrote a book. Thank you for sharing, Sir.